William J. Phd Link Sells 41,500 Shares of Glaukos Corp (GKOS) Stock

Glaukos Corp (NYSE:GKOS) Director William J. Phd Link sold 41,500 shares of the stock in a transaction on Thursday, November 15th. The shares were sold at an average price of $57.62, for a total value of $2,391,230.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

William J. Phd Link also recently made the following trade(s):

  • On Tuesday, November 13th, William J. Phd Link sold 14,475 shares of Glaukos stock. The shares were sold at an average price of $58.01, for a total value of $839,694.75.

NYSE GKOS traded up $2.36 during trading hours on Thursday, hitting $59.47. The company had a trading volume of 422,539 shares, compared to its average volume of 564,212. Glaukos Corp has a 1-year low of $23.08 and a 1-year high of $70.91.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Wednesday, November 7th. The medical instruments supplier reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.05). Glaukos had a negative net margin of 8.13% and a negative return on equity of 9.26%. The company had revenue of $43.91 million during the quarter, compared to analyst estimates of $41.65 million. During the same quarter in the prior year, the company earned $0.04 EPS. The business’s revenue was up 8.7% on a year-over-year basis. On average, sell-side analysts anticipate that Glaukos Corp will post -0.55 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in the company. MetLife Investment Advisors LLC boosted its stake in shares of Glaukos by 13.5% during the second quarter. MetLife Investment Advisors LLC now owns 15,446 shares of the medical instruments supplier’s stock worth $628,000 after buying an additional 1,838 shares during the period. Bank of Montreal Can boosted its stake in shares of Glaukos by 5.9% during the third quarter. Bank of Montreal Can now owns 39,000 shares of the medical instruments supplier’s stock worth $2,532,000 after buying an additional 2,190 shares during the period. Great West Life Assurance Co. Can boosted its stake in shares of Glaukos by 112.0% during the second quarter. Great West Life Assurance Co. Can now owns 4,240 shares of the medical instruments supplier’s stock worth $172,000 after buying an additional 2,240 shares during the period. Principal Financial Group Inc. boosted its stake in shares of Glaukos by 10.2% during the first quarter. Principal Financial Group Inc. now owns 29,787 shares of the medical instruments supplier’s stock worth $918,000 after buying an additional 2,746 shares during the period. Finally, Artisan Partners Limited Partnership boosted its stake in shares of Glaukos by 0.7% during the second quarter. Artisan Partners Limited Partnership now owns 426,246 shares of the medical instruments supplier’s stock worth $17,323,000 after buying an additional 2,845 shares during the period.

GKOS has been the subject of several research analyst reports. Stephens restated an “overweight” rating and issued a $57.00 price objective on shares of Glaukos in a research note on Wednesday, August 29th. JPMorgan Chase & Co. upgraded shares of Glaukos from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $42.00 to $75.00 in a research note on Wednesday, August 29th. Berenberg Bank initiated coverage on shares of Glaukos in a research note on Thursday, August 30th. They issued a “hold” rating and a $57.00 price objective for the company. Wells Fargo & Co upped their price objective on shares of Glaukos from $50.00 to $74.00 and gave the company an “outperform” rating in a research note on Thursday, August 30th. Finally, Piper Jaffray Companies upped their price objective on shares of Glaukos to $73.00 and gave the company an “overweight” rating in a research note on Friday, August 31st. Four research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $58.20.

TRADEMARK VIOLATION WARNING: This report was originally reported by WKRB News and is owned by of WKRB News. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.wkrb13.com/2018/11/16/william-j-phd-link-sells-41500-shares-of-glaukos-corp-gkos-stock.html.

About Glaukos

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma.

Featured Story: What is an Initial Public Offering (IPO)?

Insider Buying and Selling by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply